Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oph1 vs Restasis in healthy volunteers
NCT05184517Phase 1Completed
- Sponsor
- OphRx
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Oph1 in dry eye syndrome (DED) (2 arms), sponsored by OphRx. Primary endpoint: Drop Discomfort Visual Analog Scale Score at Day 5. Started Jan 2023; status: completed.
02
Drugs
Oph1
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT05184517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184517.